PubRank

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Clinical Trial ID NCT00932893

PubWeight™ 58.55‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00932893

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 14.78
2 A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011 4.22
3 Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011 2.88
4 Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol 2010 2.26
5 Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol 2015 2.26
6 Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol 2012 1.97
7 Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012 1.88
8 Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011 1.65
9 Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011 1.55
10 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 1.48
11 Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012 1.45
12 Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011 1.31
13 Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014 1.19
14 Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 2011 1.10
15 Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 2014 1.07
16 Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol 2012 1.06
17 New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 2011 1.01
18 Lung cancer in the era of precision medicine. Clin Cancer Res 2015 0.96
19 Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 2011 0.96
20 Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 2015 0.96
21 Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. Br J Clin Pharmacol 2016 0.91
22 Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. Onco Targets Ther 2015 0.90
23 Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012 0.89
24 EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. Oncoimmunology 2015 0.86
25 Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol 2013 0.86
26 Crizotinib: A comprehensive review. South Asian J Cancer 2013 0.85
27 ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Med Rep 2011 0.85
28 Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther 2011 0.83
29 Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med 2012 0.82
30 Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr Oncol 2012 0.81
31 Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer 2012 0.80
32 The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem 2014 0.80
33 Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol 2013 0.79
34 Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med 2016 0.78
35 ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget 2016 0.76
36 Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clin Chem Lab Med 2011 0.76
37 Future directions in the evaluation of c-MET-driven malignancies. Ther Adv Med Oncol 2011 0.76
38 Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs Future 2011 0.75
39 Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol 2011 0.75
Next 100